NIRS in PDA VLBW Infants
Launched by SINGAPORE GENERAL HOSPITAL · Mar 23, 2015
Trial Information
Current as of June 29, 2025
Completed
Keywords
ClinConnect Summary
Aim of study:
To conduct an observational study to collect cerebral and renal perfusion data through NIRS before and after treatment of PDA by medication or by PDA ligation. The data post treatment would form the basis for normative baseline data in VLBW preterm newborn babies, particularly in the Asian population.
Study population/inclusion criteria:
VLBW newborn babies with hemodynamically significant PDA by echocardiography.
Exclusion criteria:
Major malformations Moribund patients
Protocol:
Consent will be obtained from parents of eligible newborns before treatment of hemodynamic...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • VLBW infants with hemodynamically significant PDA by echocardiography
- Exclusion Criteria:
- • Major malformation
- • Moribund
About Singapore General Hospital
Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Woei Bing Poon, MRCPCH
Principal Investigator
Singapore General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials